Radioligand therapy is a rapidly developing therapeutic approach for metastatic castration resistant prostate cancer (mCRPC). Human kallikrein-related peptidase 2 (hK2), a tumor-associated member of the kallikrein family and cancer-specific target, shares significant homology to prostate-specific antigen and is minimally expressed in normal non-prostate tissues.

Read more here.

Source: ASCO GU 2022

The ARANOTE study, an international, multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, evaluates the efficacy and safety of darolutamide plus ADT in patients with mHSPC

Read more on the study here.

Source: ASCO GU 2022

On this subject, we also found an article in The New England Journal of Medicine, Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. In this trial involving patients with mHPC, overall survival was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points.

Robot-assisted radical prostatectomy (RARP) is associated with poorer post-operative urinary continence in older men.
An Australian study concluded that urinary bother and pad-usage post-RARP are excellent in young men but worsen with age. Older patients were only slightly more likely to be “significantly bothered” by incontinence despite higher pad-usage.

Read the abstract here.

Chief Editor of the Journal of Urology, Dr. Van den Bergh, commented that “besides age, membraneous urethra length (MUL), body mass index, and others, are known factors impacting on post-operative continence rates.” Read his full comments here.

Source: UROONCO Prostate cancer – Article of the Month

“Active Surveillance: A Virtual Round Table on Lessons learned from Recent and Actual Specialists and Patient Testimonials. What is really fundamental to know?”

Led by Cosimo Pieri (IT) and Tania Estapé (ES) – Board members Europa Uomo

Video-clips by Hendrik Van Poppel, Monique Roobol, Riccardo Valdagni, Lara Bellardita, Chris Bangma

March 29, 2022 from 5:45 pm to 6:45 pm CET

Zoom-link: https://us02web.zoom.us/j/9212308719?pwd=SVZmSVhlcGZ3c2FNZEhzUm5Sa1grUT09

PROGRAMME:

1. Welcome
2. In this webinar, EUomo will focus on the following questions:

• How Prostate Cancer treatments evolved and what is Active Surveillance?
• How Early Diagnosis provides better Quality of Life and when it is possible to choose Active Surveillance strategy?
• How and when Active Surveillance was developed and which are the scientific evidences of solidity of Active Surveillance?
• Which support to patients may be given by local patient organizations?
• Which psychological attitude by patients and medical world is needed when facing the Active Surveillance journey?

3. Conclusion

The GA22 Programme Committee has met last week and defined the programme for the Europa Uomo Masterclass and General Assembly.

The Europa Uomo members have received the registration document together with a call out for Board Candidates, for Motions & Proposals and for hosting the GA 2023. Deadline for all April 25th, 2022.

Thursday, June 9th 2022:

<15:00: Arrival Board members

All day: GA Delegates arrive in Leusden

15:00–18:00 (or 16:00-19:00 depending arrival times Board members): Board meeting

19:00: Dinner

Friday, June 10th  2022:

09:00–10:00:  Masterclass part I: How to use EUPROMS with your membership?

10:00–17:00: Masterclass part II

• Welcome with coffee – distribution headsets
•  Welcome
  • Kees van den Berg, Chairman Prostaatkankerstichting
• Opening by chairman of the day
  • Erik van Muilekom, Nursing specialist AGZ Antoni van Leeuwenhoek
• 25 year Prostaatkankerstichting: from patient to equal professional
  • Dr. ir. Guus de Vries, Chairman Advisory Board Prostaatkankerstichting
• Early detection of prostate cancer
  • Prof. dr. Monique Roobol-Bouts, Professor of decision making in urology and epidemiologist, Erasmus MC
  • Prof. dr. Hein Van Poppel, European Association Urology, KU Leuven
• Closing morning programme
  • Herman Zondag, on behalf of AFAS Theater

Lunch

• New possibilities of radiation therapy MR-Linac
  • Prof. dr. ir. Jan Lagendijk, Professor of Clinical Physics, UMC Utrecht
  • Dr. Jochem van der Voort van Zyp, Radiation oncologist, UMC Utrecht
• Developments in systematic treatment in metastatic prostate cancer
  • Dr. Niven Mehra, Internist oncologist, Radboudumc

Tea break

• Possibilities of lutetium treatment in men with metastatic prostate cancer
  • Dr. Jules Lavalaye, Nuclear Medicine, Antonius Hospital
• Quality of Life and prostate cancer. The EUPROMS study.
  • André Deschamps, Chairman Europa Uomo
• Musical closing by pianist Jan Vayne
• Drink

19:00: Dinner

Saturday, June 11th 2022:

8:30–12:15: GENERAL ASSEMBLY EUROPA UOMO 2022 (DRAFT PROGRAMME)

• Welcome by the Chair
• Adoption Agenda and approval minutes Special GA 26.03.2021 + GA 19.06.2021
• Questions to the supervisor of the elections
• Chairman’s Report
• Treasurer’s Report (Audited accounts 2021, Projected outcome 2021, Budget 2022 & 2023, Queries from delegates, Discharge of the Board)
• Proposals and Motions (received from members)
• Address by Candidates for Board Election
• Election to the Board (Explanation voting rules by the voting supervisor, Distribution of ballot papers to voting delegates, Voting – Collection of Ballot Papers – Counting by 2 counters)
• Varia / Any Other Business
• Short adjournment of the new Board to meet and elect Officer

Coffee Break

• Announcement from the Board on the Election of Officers
• Date and Venue of GA 2023
• Closing Remarks by the New Chairman

12:30–22:30: Social activity + dinner in Rotterdam

Sunday, June 12th, 2022: Departure

The European Organisation for Research and Treatment of Cancer (EORTC) is pleased to announce that Professor Winette van der Graaf now takes over as new EORTC President – effective as of February 11^th, 2022.

‘Prostate cancer in heterosexual, gay and bisexual men‘

Prostate cancer patients suffer from a double taboo: the cancer itself and the side effects of treatment that can undermine their quality of life and their relationship with their partner. As a result, very few men with prostate cancer open up about it, in contrast to the many women who talk about their breast cancer in the media. Prostate cancer treatment can cause sexual impotence, incontinence, inflammation of the rectum, anxiety, depression and risk of suicide. A declining in quality of life and feeling of loss of powers and autonomy in some cases, are leading to psycho-social and relationship problems.